Institute for Biomedical Research and Innovation, National Research Council (CNR), Palermo, Italy.
Institute for Biomedical Research and Innovation, National Research Council (CNR), Palermo, Italy; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Biochim Biophys Acta Mol Cell Res. 2020 Sep;1867(9):118743. doi: 10.1016/j.bbamcr.2020.118743. Epub 2020 May 15.
Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. These emerging therapies are very promising for the prevention and treatment of liver diseases. One promising druggable molecular target is the multifunctional serine/threonine kinase, glycogen synthase kinase 3 (GSK-3). In this review, we discuss conditions in which GSK-3 is implicated in liver diseases. In addition, we explore newly emerging drugs that target GSK-3β, as well as their potential use in and impact on the management of liver diseases.
肝脏疾病，包括由乙型肝炎或丙型肝炎病毒感染引起的肝炎、非酒精性脂肪性肝病和肝细胞癌，由于治疗方法有限，对整体健康构成重大挑战。因此，迫切需要为这些疾病的治疗开发新的治疗策略。更好地了解肝脏疾病发病机制中涉及的信号通路，可以帮助提高新兴疗法的疗效，这些疗法主要基于药理学方法，影响一个或多个涉及关键信号转导通路的特定分子。这些新兴疗法在预防和治疗肝脏疾病方面非常有前途。一个有前途的可药物治疗的分子靶标是多功能丝氨酸/苏氨酸激酶糖原合酶激酶 3（GSK-3）。在这篇综述中，我们讨论了 GSK-3 参与肝脏疾病的情况。此外，我们还探讨了靶向 GSK-3β的新型新兴药物，以及它们在肝脏疾病管理中的潜在用途和影响。
